NCT00005845View on ClinicalTrials.gov

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

September 30, 2009

Conditions

Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRefractory Anemia With Ringed SideroblastsRefractory Cytopenia With Multilineage Dysplasia

Interventions

DRUG

tipifarnib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00005845 - Tipifarnib in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter